MassChallenge

HeroSupport is a medical device manufacturing company founded in 2019 and based in Veyrier, Geneva. The company specializes in creating medical immobilization devices designed to enhance patient comfort during clinical procedures. Its innovative technology transforms imaging and treatment tables into personalized support solutions, specifically catering to the needs of patients undergoing prone breast radiotherapy. This approach allows patients to benefit from tailored support, eliminating the need for them to adjust to the standard table. By improving patient comfort, HeroSupport enables healthcare providers to deliver more effective and cost-efficient cancer treatment.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

electronRx specializes in digital medicine solutions for chronic disease management. They develop personalized healthcare platforms that monitor cardiovascular health remotely, enabling patients to self-manage their conditions with clinical oversight.

Benten Technologies is a social impact company dedicated to democratizing healthcare through digital therapeutics. Its platform focuses on enhancing services for expectant mothers, supporting healthy living, providing health education, and offering screening devices, aiming to improve access to care and quality of life for diverse patient populations.

XN Health is a medical device company founded in 2021 and based in Texas, USA. The company focuses on developing innovative healthcare solutions to assist mechanically ventilated patients in weaning off ventilators more efficiently. Its primary product utilizes phrenic nerve stimulation to induce diaphragm contractions, thereby mitigating the risks of diaphragm dysfunction associated with prolonged mechanical ventilation. By enhancing the weaning process, XN Health aims to improve patient outcomes and facilitate recovery in critical care settings.

YouthBio Therapeutics specializes in developing tissue-specific gene therapies based on partial cellular reprogramming, aiming to restore youthful gene expression in targeted cells. Its initial focus is on rejuvenating the brain to treat diseases like Alzheimer's by promoting cellular renewal in neurons and other brain cell types.

Dart Biosciences works in the healthcare industry. It creates tailored gene therapies for a variety of uncommon and prevalent disorders.

SAFE4BOTH is a care strategy that supports moms with OUD and their substance-exposed child by promoting optimal prenatal and postpartum care and support. The platform supports moms in their recovery process by utilizing evidence-based treatment plans, case management, and behavioral health approaches.

Red Arrow Therapeutics is a biotechnology company developing innovative cancer therapies. It focuses on systemic cytokine delivery, targeted intratumoral activation, and enhancing biological potency to maximize drug efficacy while minimizing toxicity.

OSEM provides best-in-class solutions to nanodrugs manufacturing that revolutionize healthcare, to revolutionize drug delivery systems and contribute to the advancement of life-saving therapeutics.

Form Biologics is a new platform technology for the injectable formulation of biologic medicines in order to make treatments more patient-friendly and efficacious.

Developer of cancer drugs designed to help treat solid tumors. The company focuses on treating cancer diseases using biomaterials, enabling healthcare professionals to improve survival rates, reduce adverse effects, and offer new hope to patients.

Corveus Medical is a medical device company focused on innovative solutions for preventing heart failure. The company is developing a neuromodulation device designed to perform nerve ablation through a catheter-based approach. This minimally invasive technology aims to effectively target and access specific tissues, offering a novel treatment option for heart failure. By addressing both the clinical and economic challenges associated with this condition, Corveus Medical seeks to improve patient outcomes and enhance the overall management of heart failure.

Ember Sleep develops innovative medical devices for treating sleep apnea. Their platform offers a comfortable, effective, and non-invasive solution to improve sleep quality.

Arnav Biotech is a biotechnology company that operates as a Contract Development and Manufacturing Organization (CDMO), specializing in mRNA technology. It offers services for the design, development, and manufacturing of custom and cataloged mRNA products, supporting research, therapeutics, and vaccines. By providing these services, Arnav Biotech enables researchers to concentrate on their specific areas of interest, thereby democratizing access to mRNA-based life sciences.

Pharmesol is a clinical services company that develops a platform to automate follow-up care for medications. The platform uses artificial intelligence to automate calls and messages, streamlining communication among patients, providers, and payers, and supports data management with recorded documentation. This enables patients and doctors to receive personalized support around the clock.

PlusVitech specializes in developing safe and effective therapeutic treatments for cancer patients. Its innovative approach focuses on non-invasive genetic cancer detection using small molecule and monoclonal antibody therapies, aiming to enable early diagnosis and treatment.

Anviron is a biotechnology company that develops small-molecule inhibitor therapies for aggressive and late-stage cancers. The company focuses on scientific research to halt or shrink tumor growth in cancers such as pancreatic, breast, gastric, and cervical cancers, aiming to provide healthcare professionals with potential new treatment options. It employs a team of scientists, doctors, and clinicians dedicated to advancing cancer therapies.

Narval is a biotechnology company specializing in the development of synthetic antibody mimetic proteins (AMPs). These AMPs are significantly smaller than conventional antibodies, yet retain their biological functionality. They offer several advantages, including the ability to penetrate tissue barriers, generate limited immune reactions, target small and hard-to-reach antigens, and withstand heat. This technology enables Narval to create novel first-in-class immunotherapeutics for diseases previously challenging to treat using monoclonal antibodies. Their focus includes respiratory, eye, and autoimmune diseases, with delivery methods such as inhaled antibodies, eye drops, and transdermal patches. Narval leverages machine learning and artificial intelligence to optimize its drug development capabilities.

Stellate Therapeutics is a global biotechnology company specializing in the development of small molecules derived from human gut bacteria into personalized therapies for neurological diseases. The company's platform has generated a portfolio of new drug candidates, with capabilities spanning discovery, screening, production, and diagnostic development.

Speratum is a biopharmaceutical company focused on microRNA-directed oncology therapies. The Company was founded in 2014 by Christian Marín-Müller, Ph.D. and is dedicated to the development of a patented treatment for pancreatic cancer based on the combination of tumor suppressive microRNA molecules and nanoparticle-based drug delivery technologies. The Company is currently entering the final stage of preclinical trials for the pancreatic cancer therapy, while simultaneously expanding the patent’s coverage to incorporate other types of cancer and non-cancer indications and illnesses and expanding its intellectual property (IP) portfolio with complementary technologies in the fields of nanotechnology, medical devices and veterinary medicine.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

Although the #1 indicator of therapeutic success is the patient-therapist fit, 1 in 2 adults quit therapy due to a lack of therapist fit. Getting this match wrong is costly for health insurers and therapists. Unmute focuses on increasing the match and long term success-rate for patients seeking therapy using machine learning algorithms.

Canopie is a mental health care company focused on addressing maternal depression and anxiety through a digital platform. The platform offers customized, audio-based programs and automated coaching that utilize clinically validated therapeutic techniques, including adaptations of cognitive behavioral therapy and compassion-focused treatment. By collaborating with cities, payers, health systems, and healthcare providers, Canopie aims to deliver effective and affordable care for mothers, overcoming barriers such as cost, scheduling, time, and stigma. The company's innovative approach is designed to support pregnant women and new mothers in preventing and treating common mental health challenges, making it a scalable solution in maternal mental health care.

Oculogenex is a biopharmaceutical company founded in 2020 and based in La Habra, California. It specializes in the development of gene therapies aimed at treating retinal disorders. The company’s innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced cell death, a condition linked to macular degeneration. By focusing on these therapies, Oculogenex seeks to enable researchers to enhance the detection and treatment of retinal-related disorders, contributing significantly to advancements in this critical area of medical research.

miniMarrow presents a new disruptive therapeutic approach for the in-situ production of blood components in leukemic patients to replace weekly and burdensome transfusions markedly increasing patient quality-of-life. miniMarrow is operating in stealth mode. miniMarrow was established in Renens, Vaud

INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.

Ronawk is a biotechnology company specializing in the development of T-Block technology that produces patient-specific biologics for the treatment of various diseases, including cancer, organ injuries, and burns. The company's proprietary method allows for the growth of primary stem cells in a three-dimensional environment, preserving the essential characteristics of these cells outside the human body. This innovative approach enables the rapid expansion of stem cells, facilitating their use in early-stage diagnostics and the repair of damaged tissues. Ronawk's technology not only enhances the efficiency of growing human cells but also supports tissue generation and disease modeling, making significant contributions to the fields of regenerative medicine and reconstructive surgery.

Opsin Biotherapeutics specializes in the development of gene therapies based on opsins, a class of light-sensitive proteins. The company's primary focus is to create a pipeline of treatments for pain management, aiming to provide effective alternatives to opioids.

MyoGene Bio is a biotechnology company focused on developing innovative therapies for muscle diseases, with an initial emphasis on gene-editing treatments for Duchenne muscular dystrophy. The company employs advanced technologies to address the underlying causes of this condition, aiming to significantly improve disease progression and outcomes for patients. By targeting the root of the disorder, MyoGene Bio seeks to provide clinicians and patients with effective solutions that have a meaningful impact on the management of devastating muscle disorders.

SafetySit is a company focused on developing assistive therapeutic medical devices aimed at supporting disabled or recovering patients who struggle with core muscle strength. Its main product is a mobile backrest designed to facilitate the sitting posture of these individuals. By enabling clinicians to treat patients more effectively, SafetySit's innovation enhances the early mobilization process in recovery, allowing healthcare providers to eliminate the need for manual support during therapy sessions. This approach not only aids in patient rehabilitation but also improves the overall efficiency of clinical care.

Selmod, based in Basel's life science hub, develops innovative antibiotics targeting multi-drug resistant infections. Its first-in-class drug candidates focus on high-revenue hospital patients where first-line treatments have failed due to resistance. With a disruptive approach featuring new dual modes of action, all candidates have shown success in animal infection studies. The company aims to capture a significant share of the estimated $9 billion total available market for its three lead assets.

ModoScript is a developer of innovative digital healthcare solutions focused on enhancing remote treatment monitoring and big data analytics for high-cost specialty pharmaceuticals, particularly Oral Oncolytics. The company aims to improve the efficiency of medication and treatment protocols, ultimately leading to better patient outcomes in managing chronic diseases like cancer. By leveraging a customizable data analytics model, ModoScript provides pharmaceutical companies, health insurance providers, and medical practices with tools to assess treatment progress and support direct-to-patient clinical trials from home. The company collaborates with mail-order specialty pharmacies and in-office medically integrated pharmacies to facilitate remote treatment delivery. ModoScript is dedicated to ensuring that patients receive high-quality care regardless of their race, condition, or socioeconomic status, striving to make their solutions accessible at no cost to patients while reducing overall industry costs.

Glamorous AI develops an artificial intelligence driven drug discovery platform that accelerates pharmaceutical research by leveraging prior experimental results to identify and optimize chemical scaffolds, predict activities, and screen ultra-large chemical libraries. The platform addresses low-data, sparse, and noisy datasets, enabling the discovery of novel compounds and potential therapeutics.

Transcera is a biotechnology company that develops a lipid-based drug delivery system. This platform enables precise targeting of therapeutic molecules, allowing large molecules to cross cellular barriers for improved treatment of chronic diseases.

Asan Therapeutics utilizes a novel technology that simplifies the treatment of cancer patients to receive only a single injection instead of several painful injections.

Akttyva Therapeutics develops targeted therapeutics to address cell barrier dysfunction across multiple indications.

Founded in Italy in 2016 by Silvia Scaglione and Maurizio Aiello, React4life is a biotech company dedicated to advancing biomedical research. The company specializes in the development of MIVO®, an innovative organ-on-a-chip technology that enhances the reliability and predictability of various applications such as pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals.

BrightCure Ltd., established in 2019 and based in London, United Kingdom, specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). The company focuses on addressing recurrent and difficult-to-treat bacterial infections, a significant health issue affecting 50% of women and 12% of men globally. BrightCure's approach involves utilizing the natural microbiome to reduce harmful bacteria and replenish beneficial bacteria in the vaginal flora, thereby boosting the immune system to promote urinary tract health. The company has garnered recognition through various competitions and accelerators, including selection for Indiebio, the world's largest biotech accelerator.

TissueLabs is the platform for creating organs and tissues in the lab. We offer biomaterials, equipment, and services to support tissue engineering and regenerative medicine. Our products are created to allow performing state-of-the-art research, from drug discovery to organ fabrication. Currently, we are focused on attending the academic life sciences market. In the future, our mission is to fabricate lab-grown tissues and organs, for both research and therapeutic applications.

BioEclosion is a biotechnology company specializing in the development of user-friendly, rapid diagnostic tools. Its core technology, Celifast, is a non-invasive method for detecting celiac disease, validated and patented. The company aims to expand this platform to other emerging diseases, using molecular biomarkers for swift identification. BioEclosion's device comprises a single-use cartridge tailored to each application and a portable, battery-operated reader, making it versatile for human and veterinary health, as well as food and environmental safety.

Kobara Medical specializes in developing innovative medical therapeutic devices aimed at addressing heart failure with preserved ejection fraction (HFpEF), a condition where the heart struggles to fill its main pumping chamber effectively. This condition affects over three million people and is growing. The company's unique, minimally invasive device leverages the heart's transverse pericardial sinus for neuromodulation therapies, providing an alternative to traditional cardiac rhythm management methods that often require multiple leads or invasive procedures. By utilizing this approach, Kobara Medical offers a novel solution that combines multiple leads into one, enabling multi-chamber pacing from outside the blood vessels.

Matricelf is a biotechnology company focused on advancing tissue engineering and regenerative medicine. Founded in 2019 by Professor Tal Dvir from Tel Aviv University, the company specializes in the 3D printing of tissues and organs, utilizing a proprietary decellularization process that extracts stromal cells and extracellular matrix from small biopsy samples. This process generates a thermo-responsive hydrogel, which is then combined with reprogrammed induced pluripotent stem cells to create functional tissues through a patent-pending methodology. Matricelf is particularly dedicated to developing spinal cord implants for patients with traumatic injuries, aiming to restore neuronal activity and enhance motor functions, thereby improving patients' quality of life and facilitating their reintegration into the community.

UpLift Health Inc., based in Atlanta, Georgia, specializes in developing a digital application aimed at treating depression through cognitive behavioral therapy (CBT). Founded in 2018, the company offers a structured program that consists of twelve weekly sessions, each lasting approximately 40 minutes, designed to teach users effective coping skills. The application incorporates chatbot-guided interactions, allowing users to engage with mental exercises and receive feedback. Additionally, it provides daily tools for users to apply learned skills in their everyday lives. Preliminary research indicates that UpLift's program can significantly reduce symptoms of depression, with a reported reduction of 52% in pilot studies. The company is focused on its mission to assist one million individuals in overcoming depression.

Litesprite, Inc. is a Bellevue, Washington-based company that develops mobile games aimed at helping individuals manage chronic health conditions, particularly stress, anxiety, and depression. Its flagship product, Sinasprite, is a video game designed to guide users through prescribed mental health treatments, enabling them to track their progress and engage with coping mechanisms in real time. The platform provides valuable data to clinicians, allowing them to understand the effectiveness of various treatment options for their patients. Litesprite's innovative approach combines proven medical treatments with interactive gaming to enhance patient engagement and facilitate communication between patients and healthcare providers. The company aims to create a suite of games addressing various health conditions, leveraging the emotional engagement of gaming to promote better health outcomes. Since its incorporation in 2013, Litesprite has been recognized for its potential to make a significant impact in healthcare, winning accolades such as the Robert Wood Johnson Foundation's Games to Generate Data Challenge.

Naviday Health develops a personalized, AI-guided care platform focused initially on menopause. It empowers users with tailored insights, symptom tracking, and holistic support, bridging the gap between traditional care and real-world health needs.

Tremedics develops bioresorbable technology for congenital heart disease patients with congenital heart disease need devices that resorb within their bodies as they grow. Their technology utilises a minimally invasive surgery procedure for stent delivery and permits vessel growth as the stent resorbs in the body.

Octarine Bio is a biotechnology company based in Copenhagen, Denmark, founded in 2018. The company specializes in the research and development of cannabinoid and psilocybin derivatives, utilizing synthetic biology to create a range of natural and novel compounds. Through its biosynthetic platform, Octarine Bio focuses on producing superior cannabinoids aimed at the pharmaceutical industry, improving pharmacokinetic and therapeutic properties. Its innovative approach enables healthcare professionals to better address neurological and psychological disorders, ultimately enhancing health and well-being.

Thinks Works is an early-stage biomedical company focused on improving the treatment of adolescent scoliosis, a severe spinal curvature in children. Founded by Dr. Ryan C. Murdock, the company aims to address the limitations of current treatment methods, which involve custom-made hard plastic braces that can be uncomfortable and have poor patient compliance. Thinks Works is developing a novel, flexible brace that promises enhanced patient comfort, improved compliance, and better treatment outcomes at a lower total cost. The device also provides real-time treatment data, enabling healthcare providers to monitor and adjust treatment plans as needed.

PROSPERiA is a social impact company spun off from the MIT Media Lab. It aims to enhance early detection and treatment of chronic diseases in emerging markets using Artificial Intelligence-based solutions.

Sano Chemicals is an early‑stage biotechnology company that develops novel anti‑infectives for clinical and agricultural use. The company focuses on antifungal treatments for human infections such as nail, skin, and systemic diseases, and on bio‑control methods to protect crops from fungal pathogens. Its flagship compound, occidiofungin, was discovered by researchers at Mississippi State University and Texas A&M University and is being advanced for both medical and agricultural applications. In addition to antifungal work, Sano Chemicals explores therapies against antimicrobial‑resistant fungi and bacteria and investigates potential uses in oncology, aiming to improve patient outcomes and support a sustainable food supply.

Bloomsbury is a company that leverages Artificial Intelligence and Big Data to enhance the pharmaceutical industry. It focuses on identifying new indications for existing drugs, aiming to streamline the drug discovery process. By utilizing advanced technologies, Bloomsbury seeks to reduce the time, costs, and risks associated with bringing new therapeutic options to market. Through these innovative approaches, the company is positioned to make significant contributions to the efficiency and effectiveness of drug development.

OrganoTherapeutics is a company focused on developing medical drugs aimed at treating Parkinson's disease. It utilizes advanced human-specific mini-brain models that accurately replicate the pathology of Parkinson's disease for the discovery and development of effective drug candidates. By employing three-dimensional models derived from both healthy individuals and patients with Parkinson's disease, OrganoTherapeutics identifies the therapeutic potential of various compounds and analyzes data using artificial intelligence. This innovative approach facilitates the screening of new molecules, allowing researchers to advance novel drug candidates. The company has already developed proprietary drug candidates and has access to extensive libraries for further research and development.

Neurosoft Bioelectronics specializes in developing soft, implantable electrodes designed to interface with nervous tissues. Their flagship product, SOFT ECoG, is a subdural electrode used for recording and stimulating the brain's surface, offering improved recordings, reduced current speed, minimized MRI artifacts, enhanced bio-integration, and precise anatomical targeting.

Marigold Health operates a social network community platform that provides AI-augmented chat support groups designed to assist individuals with behavioral health needs. By facilitating anonymous text-based group therapies, the company enables patients dealing with mental health and substance use conditions to connect and support one another. These support groups are complemented by the involvement of recovery coaches who help participants formulate personalized recovery plans. Marigold Health partners with treatment providers and managed care organizations within the Medicaid market, aiming to enhance patient engagement while allowing care teams to manage increased capacity effectively. Through its innovative approach, the company offers on-demand, stigma-free support for individuals seeking to improve their mental health.

Tzofen is a biotechnology company focused on developing a novel biological platform aimed at treating various types of cancer. This innovative platform has demonstrated the ability to eliminate cancer growth both in vitro and in vivo, highlighting its potential to significantly impact cancer treatment. By advancing this technology, Tzofen seeks to contribute to saving millions of lives affected by cancer.

Onena Medicines is a biotechnology company developing innovative biological medicines. It focuses on addressing large unmet clinical needs for breast cancer and other serious orphan illnesses.

Aniluxx Biotechnology, Inc. is a biopharmaceutical company focused on developing innovative topical therapeutics for companion animals affected by skin diseases. Founded in 2019 and based in Chapel Hill, North Carolina, the company aims to enhance the health and well-being of pets by creating treatments for conditions such as atopic dermatitis and osteoarthritis. Aniluxx Biotechnology’s approach leverages a pipeline of topically formulated therapeutics based on compounds that have demonstrated safety and efficacy in humans. These therapeutics are designed to be easy to apply and virtually unnoticeable, minimizing the harsh side effects often associated with systemic medicines. Through its commitment to improving animal care, Aniluxx Biotechnology seeks to provide pet owners with effective solutions for managing their pets' health issues.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

InvivoSciences specializes in phenotypic compound screening services, focusing on first-in-class drug discovery and drug repositioning. The company's unique approach combines tissue engineering technology with assay automation and sample miniaturization to provide a rapid and cost-effective platform for therapeutic discovery.

MSL Pharma is a pharma company that performs ideation, analysis and identifies the solutions to treat diseases.

Marigold Health operates a social network community platform that provides AI-augmented chat support groups designed to assist individuals with behavioral health needs. By facilitating anonymous text-based group therapies, the company enables patients dealing with mental health and substance use conditions to connect and support one another. These support groups are complemented by the involvement of recovery coaches who help participants formulate personalized recovery plans. Marigold Health partners with treatment providers and managed care organizations within the Medicaid market, aiming to enhance patient engagement while allowing care teams to manage increased capacity effectively. Through its innovative approach, the company offers on-demand, stigma-free support for individuals seeking to improve their mental health.

Embleema is a health data platform focused on improving the drug discovery process and accelerating the development of new treatments. The company empowers patients to take ownership of their medical data, facilitating direct connections with research studies and allowing patients to be compensated for sharing their information. By enhancing the collection and sharing of real-world evidence, Embleema aims to transform the traditional linear model of drug approval into a more efficient iterative process. This approach enables the healthcare system to generate regulatory-grade evidence, including genomic sequences and data on microbial pathogens, thereby reducing the time and costs associated with bringing life-saving drugs to market, particularly for patients with rare diseases.

Artiria Medical develops innovative guidewire systems designed to enhance navigation during neurovascular procedures. Its products feature dynamic tip deflection, superior torque transmission, a high-quality hydrophilic coating, smooth intravascular navigation, adjustability, and a controlled tip deflection mechanism. These devices aim to facilitate complex interventions, reduce procedure-related risks, and improve overall efficiency.

CellSpring is a biotechnology company based in Zurich, Switzerland, that develops 3D tissue models for biological research. Its core offering, the 3D Bloom platform, enables rapid creation of biomimetic microtissues independent of cell type, supporting in vitro studies and drug development. The platform emphasizes speed, reliability, versatility, and ease of use, improving the fabrication of 3D cell cultures for diverse experimental applications.

Tellus Therapeutics is a biopharmaceutical company based in Hillsborough, North Carolina, founded in 2018. The company focuses on developing innovative small molecules derived from human maternal breast milk to address unmet medical needs in newborns, specifically targeting perinatal brain injury. Its lead drug candidate promotes the regeneration of myelin-producing oligodendrocytes and aims to reverse white matter injury in premature infants. This therapeutic approach enables healthcare providers to offer treatment to all babies at risk of brain injury, ultimately striving to improve neurodevelopmental outcomes for affected children.

Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

Encapsulate is a biotechnology company focused on developing automated tumor-on-a-chip systems that facilitate personalized cancer treatment. The company's innovative technology allows for the growth of patients' cancer cells outside the body, creating micro tumors that can be preserved and utilized to assess the efficacy of various chemotherapy and biotherapeutic drugs. By screening the response profile of cancer patients to these treatments, Encapsulate aims to enable oncologists to tailor effective treatment regimens, improving outcomes in cancer care.

Pocket Innovations is a medical device company focused on addressing the common complication of pocket hematoma that arises from implant procedures, specifically for pacemakers, defibrillators, and Deep Brain Stimulation devices. The company's innovative device represents the first preventative solution designed to help mitigate the formation of these costly hematomas. By providing medical practitioners with a method to prevent this frequent post-operative complication, Pocket Innovations aims to enhance patient outcomes and improve operational efficiency in medical procedures involving implantable devices.

Animatus Biosciences develops technology that can control networks of genes to regenerate cardiac tissue. Their two mRNA combinations, AN-153, are modified to make altered proteins that regulate key cellular pathways in cardiac cells.

Strand Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in genetically programming mRNA to deliver innovative therapies aimed at enhancing patient outcomes. Founded in 2017, the company develops mRNA programming technology that allows for precise control over the location, timing, and intensity of therapeutic protein expression within the body. By employing mRNA-encoded logic circuits, Strand Therapeutics can achieve cell-type specific expression by detecting unique miRNA signatures and modulating protein dosage in response to externally administered small molecules. The company focuses on creating gene therapies powered by synthetic biology, including immunotherapies designed to enable cells to produce target cancer-killing proteins, thereby strengthening the body's immune response against cancer.

OrthoBistro is a healthcare company focused on enhancing orthopedic care through a comprehensive platform that facilitates meaningful interactions between patients and healthcare providers. The company offers a range of services, including patient education, telemedicine, and physical therapy tools tailored to individual lifestyles. By addressing orthopedic questions that arise during therapy, OrthoBistro empowers patients to communicate effectively with their therapists, thereby improving the overall quality of care and patient experience. Through its innovative approach, OrthoBistro aims to transform the way patients engage with orthopedic healthcare.

Sinon Therapeutics is committed to enhancing the lives of individuals with debilitating neurological disorders by advancing drug delivery across the Blood Brain Barrier (BBB).

Combioxin is a clinical-stage biotechnology company focused on developing anti-virulence therapies to treat severe bacterial infections and address antibiotic resistance. Its approach centers on liposome-based constructs engineered to neutralize virulence factors produced by pathogens, with the aim of restoring health in critically ill patients, including those with severe bacterial pneumonia.

CrystalsFirst is a company providing structure-guided drug discovery technologies that leverage protein crystal data to accelerate screening and lead optimization. It develops methods to stabilize fragile protein crystals for screening and offers SmartSoak for small-molecule probes, SmartLib libraries for fragment-based discovery, and SmartRefine software for automated refinement of crystallographic data, together enabling high-confidence assessment of protein–ligand interactions. The company also creates atom-resolved 3D models that illustrate the geometry of protein–drug interactions. Its MAGNET platform integrates crystal-structure-first strategies with high-performance structural biology, large-scale computational modeling, generative AI and medicinal chemistry to identify novel molecules and druggable binding pockets for challenging targets. The platform supports rapid hit generation, scaffold diversification, and property optimization, aiding rational design from crystal structures and expanding chemical space. CrystalsFirst serves the biopharmaceutical sector, helping to tailor compounds for high affinity and uncover new modes of action across protein families and modalities. The company was founded in 2018 and is based in Marburg, Germany.

Terapet specializes in advanced proton therapy for cancer treatment. Founded by physicists Christina Vallgren, Marcus Palm, and Professor Raymond Miralbell from Geneva University Hospitals, the company offers precise radiotherapy that minimizes harm to healthy cells. Incorporated in 2019, Terapet is based in Geneva, Switzerland.

The Feel Good Lab is a wellness product company focused on preventing and alleviating pain. Its products are developed to reduce chronic body pain while supporting overall health, using natural ingredients that are free from silicones and parabens and are odorless. The company emphasizes aiding the body's natural healing processes to help customers avoid pain relief pills, manage pain, improve recovery, and enhance overall well-being.

Dynamic Boundaries is developing a new lubricant to treat osteoarthritic joints. Invented by a team of researchers at Cornell University, this material binds to the cartilage or underlying bone providing significantly more lubrication when the joint is under pressure, unlike current hyaluronic acid-based products. The substance is chemically simple and uses only GRAS materials, giving them a significant advantage over anything in development.

Haima Therapeutics is a pre-clinical stage biotechnology company dedicated to developing bio-inspired therapies aimed at treating bleeding and other blood-related disorders. The company is focused on creating platelet-inspired therapeutics that address conditions where platelets are integral to disease progression, including thrombosis, inflammation, and cancer. Utilizing a novel, fully-synthetic nanoparticle-based hemostatic technology, Haima Therapeutics enhances the body's natural clotting mechanisms at the site of injury. This innovation is designed to help patients recover more rapidly from traumatic injuries, surgeries, and various blood-related ailments.

Gateway Biotechnology is a biotechnology company focused on developing science-based solutions for hearing disorders. It specializes in creating animal model systems for preclinical trials of drug candidates, new drug development, and innovative drug delivery methods.

Rezilient is a mental health coaching platform designed to support family caregivers of individuals with dementia and Alzheimer's, addressing the chronic stress and burnout they often experience. With over 8 million unpaid family caregivers in the United States—a number that continues to rise due to an aging population—Rezilient offers a personalized, science-based app that connects caregivers with trained coaches. The platform facilitates communication through video, voice, and text, allowing caregivers to receive real-time support and guidance as they develop essential skills and emotional resilience. Additionally, advanced AI and sentiment analysis are employed to provide predictive interventions, enhancing caregiver well-being. Research indicates that Rezilient's approach can significantly increase the likelihood of dementia patients remaining at home, leading to substantial savings for employers, insurers, and states by reducing long-term care costs.

Lumme Inc. is a company that specializes in developing an addiction treatment platform that integrates wearable technology, machine learning, and behavioral psychology. Founded in 2014 and based in Amherst, Massachusetts, the platform is designed to function as a personal therapist, providing timely assistance to users. By utilizing sensors on smartphones and smartwatches, Lumme's technology detects, predicts, and prevents behaviors that negatively impact health, specifically targeting addictions to smoking, alcohol, and unhealthy diets. The company's innovative passive gesture recognition technology alleviates the challenges associated with self-monitoring, making it easier for users to manage their behaviors. Lumme Inc. markets its platform to health insurance companies and corporations, aiming to enhance wellness and support addiction recovery.

NeuroKaire develops personalized psychiatry testing tools. It uses innovative technology to predict the most effective drug treatment for patients, enabling faster recovery, fewer side effects, and lower dosing.

EBAMed develops a non-invasive ultrasound-based device to monitor and treat heart motion using proton beams. Founded in 2018, the company is based in Geneva, Switzerland.

EBT Medical, Inc. is a clinical-stage company based in Boston, Massachusetts, with an additional office in Toronto, Canada. Founded in 2014, the company specializes in developing innovative, non-invasive neuromodulation therapies aimed at treating pelvic health disorders, particularly focusing on patients with overactive bladder. EBT Medical's technology is centered on the Saphenous nerve and is designed to provide discreet treatment options that enable patients to restore pelvic health function without the side effects typically associated with conventional therapies. The company emerged from scientific discoveries made at the University of Toronto and has benefited from a startup incubation program that has fostered numerous successful ventures in the past decade.

Oxalo Therapeutics develops therapies to treat rare kidney diseases and prevent recurrent oxalate-related stones, focusing on primary hyperoxaluria and other oxalate pathologies. It leverages microbiome science, translational research, and early-stage technology to create a gut-derived therapy that safely removes oxalate from the body, reducing stone recurrence and related renal complications.

MicroQuin is a biotechnology company founded in 2018 by Dr. Scott Robinson of Imperial College London and Yang Zheng of the University of Chicago. Headquartered at LabCentral in Cambridge, MA, the company focuses on developing smarter therapeutics to address challenging diseases, initially targeting cancer.

NovoThelium is a biotechnology company founded in 2015 by biomedical engineers motivated by personal experiences with breast cancer. The company specializes in developing a tissue-engineered nipple matrix aimed at improving breast reconstruction for cancer survivors. NovoThelium's innovative approach involves a decellularization process that utilizes human donor breast tissue, which has been treated to remove DNA and donor cells while preserving essential proteins and structures. This process allows patients to regenerate a nipple using their own cells, resulting in a natural appearance with appropriate projection, pigmentation, and enhanced sensation. By focusing on nipple regeneration after mastectomy, NovoThelium addresses a significant need for more natural reconstructive options in breast cancer care.

Prometheus is a biotech company. They provide solutions for veterinary and human regenerative medicine. They have developed ematik, a line of veterinary medicine products using platelet-rich plasma for cell and tissue regeneration. Their product is ematik ready, a veterinary plaster for the treatment of animal wounds in dogs, cats, and horses.

Founded in London in 2016, LIfT BioSciences develops a proprietary platform for allogeneic innate immuno-cell therapy. Its Neutrophil Only Leukocyte Infusion Therapy (N-LIfT®) enables scalable production of Immunomodulatory Alpha Neutrophils (IMAN®s) from induced pluripotent stem cells (iPSCs), offering potential mono or combo therapies.

ALAnostics is a specialty biopharmaceutical company that originated as a spin-off from the University of Geneva. It focuses on developing innovative tumor painting technology aimed at enhancing the surgical treatment of breast cancer. The company’s proprietary approach utilizes nanomedicines to create a fluorescent dye that targets early-stage tumors, facilitating real-time identification and removal during surgery. This technology, based on 5-ALA prodrugs, supports fluorescence-guided surgical procedures and incorporates light-activated antimicrobials, ultimately improving surgical outcomes and increasing the likelihood of saving patients' lives by ensuring complete tumor removal.

Rapid Graft, established in 2018 and based in Zurich, Switzerland, specializes in developing innovative medical devices for precise skin graft harvesting. Their flagship product is a novel dermatome designed to efficiently obtain small split-skin grafts, aiming to enhance chronic wound treatment and facilitate future tissue engineering needs. The company's device enables surgeons to perform skin grafting procedures more effectively, minimizing the risk of infection, scarring, and requiring fewer specialized interventions or operating room resources.

AUGMENTx is a developer of an augmented reality-based platform that aims to enhance access to rehabilitation therapies, particularly in the fields of neurology and rehabilitation medicine. Its subscription-based interface allows users to engage in therapy from home, utilizing standardized protocols and data-driven approaches tailored to individual recovery needs. The platform is designed to assist healthcare providers in monitoring and optimizing the mental health of patients facing chronic medical conditions and those requiring long-term rehabilitation. AUGMENTx's vision includes clinically validating its digital stroke rehabilitation platform and subsequently expanding its applications to address chronic pain and orthopedic injury rehabilitation programs.

Spirrow Therapeutics provides lung restoration to babies suffering from ARDS by using new proprietary methods. They provide polymer lung surfactant to low complexity synthesis and formulation, interface affinity exceeds competing agents, reduces alveolar surface tension, and fluid accumulation.

ImmunArtes is a biotechnology company focused on developing vaccines and therapeutics to combat Staphylococcus aureus (MRSA) infections. They aim to neutralize MRSA's immune evasion mechanisms, which contribute to increased antibiotic resistance.

Kernal Biologics, Inc. is a biotechnology company focused on designing and developing mRNA immunotherapies aimed at treating diseases such as COVID-19 and various cancers. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company leverages its mRNA platform to enable researchers and organizations to create vaccines and therapeutics. Kernal’s innovative approach allows specific cells to produce their own therapeutic agents. With a team that has strong connections to prestigious institutions like MIT and Harvard, as well as experience in the pharmaceutical industry, Kernal Biologics has garnered recognition for its work, winning multiple awards from notable organizations, including Amgen and NASA.

BioTrak is digital therapeutics platform company with smartphone products which deliver evidence-based, preventative treatment of stress-related disorders such as migraine, multiple sclerosis, depression, chronic pain, and anxiety. The first of a series of products is Ease: Headache and Migraine™, which was launched Q1’ 19. Three (3) billion people worldwide suffer from severe tension-type headaches and migraine. Ease, which delivers clinically-tested behavioral interventions on a mobile platform, is superior in clinical effectiveness, safety, cost, and convenience compared to the most advanced migraine drugs. Ease is positioned to be used either alone or adjunctively with conventional drug therapies. Ease: Headache & Migraine™ is digital therapeutic app that delivers clinically-proven, effective behavioral therapy. Ease has been shown to be as effective as in-office treatment, resulting in 60% reduction in headache frequency and disability. Ease is a brand new approach to addressing the severely unmet need for a scalable, affordable, safe and effective treatment option for the estimated 3 billion people who suffer from tension headache and migraine worldwide.

ReviveMed develops a precision-medicine platform that transforms untargeted metabolomic data into actionable insights. Its network-based machine learning algorithm integrates metabolomics with other molecular information, facilitating the development of therapeutics for liver diseases.

Crowdacure is a crowdfunding platform dedicated to financing life-saving medical research that often goes underfunded due to its niche or experimental nature. The company facilitates collaboration between researchers and the public, allowing anyone to contribute financially towards projects they deem important. Crowdacure aims to accelerate medical progress by challenging traditional funding methods, which have historically been slow and selective.